Effects of Probiotic Oral Intake on Plasma Chlordecone (Kepone) Concentrations in Individuals Environmentally Exposed to Pesticide in Martinique.

NANot yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

October 31, 2026

Conditions
Chlordecone (Kepone) Toxicity
Interventions
DIETARY_SUPPLEMENT

Limosilactobacillus reuteri

"The BioGaia® Gastrus probiotic capsule contains the following components: L. reuteri DSM 17938, L. reuteri ATCC PTA 6475) at 10\^8 CFU\*/day, fully hydrogenated palm oil; ascorbic acid; tangerine flavour and mint flavour.~\*Colony forming Unit"

OTHER

Placebo

The placebo capsules have the same external appearance and composition as the BioGaia® Gastrus Limosilactobacillus reuteri probiotic capsule (combination of L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475), but without the active ingredient.

Trial Locations (1)

97261

Centre Hospitalier Universitaire de Martinique - Hôpital Pierre ZOBDA QUITMAN, Fort-de-France

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

BioGaia AB

INDUSTRY

collaborator

University Hospital, Limoges

OTHER

collaborator

Regional Health Agency, Martinique

UNKNOWN

collaborator

Biological Resource Centre, Martinique

UNKNOWN

collaborator

Reims University hospital

OTHER

lead

University Hospital Center of Martinique

OTHER

NCT06026228 - Effects of Probiotic Oral Intake on Plasma Chlordecone (Kepone) Concentrations in Individuals Environmentally Exposed to Pesticide in Martinique. | Biotech Hunter | Biotech Hunter